BACKGROUND: Some children who are infected with human immunodeficiency virus type 1 (HIV-1) during the perinatal period remain asymptomatic for very long periods in the absence of antiretroviral treatment, as is the case for some adults. Our objective was to estimate the proportion of children who developed neither symptoms nor major immunological perturbations to the age of > or = 10 years in a prospective cohort of infected children who had been observed since birth. METHODS: The ongoing prospective French Pediatric Cohort includes 568 HIV-1-infected children. Here, we report the follow-up data for all 348 HIV-1-infected children who were born before 1 January 1994. Children with long-term nonprogression of infection (LTNPs) were defined as HIV-1-infected children who had been observed for at least 10 years, never received antiretroviral treatment other than zidovudine monotherapy, never developed symptoms of Centers for Disease Control and Prevention clinical category C or B, and had a CD4+ cell percentage of < 25% no more than once during follow-up. Other definitions were compared. RESULTS: The Kaplan-Meier estimate of long-term nonprogression was 2.4% (95% confidence interval, 1.1%-4.6%) at 10 years of age, and 7 children were classified as LTNPs. The Kaplan-Meier estimates decreased slightly with age, to 1.8% at 12 years of age and 1.4% at 14 years of age. Plasma HIV-1 replication rates were low (< 1000 copies RNA/mL) for 2 of the 7 LTNPs at the age of 10 years (0.6% of the total denominator). None of the routinely measured maternal or perinatal markers were significantly linked to long-term nonprogression, with the exception of the mother's Centers for Disease Control and Prevention clinical category at the time of delivery. CONCLUSIONS: Approximately 2% of children who were infected during the perinatal period displayed no immunological or clinical progression by the age of 10 years. This figure is close to that reported for adults in studies that have used similar definitions.
BACKGROUND: Some children who are infected with human immunodeficiency virus type 1 (HIV-1) during the perinatal period remain asymptomatic for very long periods in the absence of antiretroviral treatment, as is the case for some adults. Our objective was to estimate the proportion of children who developed neither symptoms nor major immunological perturbations to the age of > or = 10 years in a prospective cohort of infected children who had been observed since birth. METHODS: The ongoing prospective French Pediatric Cohort includes 568 HIV-1-infectedchildren. Here, we report the follow-up data for all 348 HIV-1-infectedchildren who were born before 1 January 1994. Children with long-term nonprogression of infection (LTNPs) were defined as HIV-1-infectedchildren who had been observed for at least 10 years, never received antiretroviral treatment other than zidovudine monotherapy, never developed symptoms of Centers for Disease Control and Prevention clinical category C or B, and had a CD4+ cell percentage of < 25% no more than once during follow-up. Other definitions were compared. RESULTS: The Kaplan-Meier estimate of long-term nonprogression was 2.4% (95% confidence interval, 1.1%-4.6%) at 10 years of age, and 7 children were classified as LTNPs. The Kaplan-Meier estimates decreased slightly with age, to 1.8% at 12 years of age and 1.4% at 14 years of age. Plasma HIV-1 replication rates were low (< 1000 copies RNA/mL) for 2 of the 7 LTNPs at the age of 10 years (0.6% of the total denominator). None of the routinely measured maternal or perinatal markers were significantly linked to long-term nonprogression, with the exception of the mother's Centers for Disease Control and Prevention clinical category at the time of delivery. CONCLUSIONS: Approximately 2% of children who were infected during the perinatal period displayed no immunological or clinical progression by the age of 10 years. This figure is close to that reported for adults in studies that have used similar definitions.
Authors: George K Siberry; Kunjal Patel; Russell B Van Dyke; Rohan Hazra; Sandra K Burchett; Stephen A Spector; Mary E Paul; Jennifer S Read; Andrew Wiznia; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-07-01 Impact factor: 3.731
Authors: Miguel A Garcia-Knight; Jennifer Slyker; Barbara Lohman Payne; Sergei L Kosakovsky Pond; Thushan I de Silva; Bhavna Chohan; Brian Khasimwa; Dorothy Mbori-Ngacha; Grace John-Stewart; Sarah L Rowland-Jones; Joakim Esbjörnsson Journal: Sci Rep Date: 2016-07-12 Impact factor: 4.379
Authors: Linda Barlow-Mosha; Victor Musiime; Mary-Ann Davies; Andrew J Prendergast; Philippa Musoke; George Siberry; Martina Penazzato Journal: J Int AIDS Soc Date: 2017-06-27 Impact factor: 5.396
Authors: Savannah Mwesigwa; Lesedi Williams; Gaone Retshabile; Eric Katagirya; Gerald Mboowa; Busisiwe Mlotshwa; Samuel Kyobe; David P Kateete; Eddie Mujjwiga Wampande; Misaki Wayengera; Sununguko Wata Mpoloka; Angella N Mirembe; Ishmael Kasvosve; Koketso Morapedi; Grace P Kisitu; Adeodata R Kekitiinwa; Gabriel Anabwani; Moses L Joloba; Enock Matovu; Julius Mulindwa; Harry Noyes; Gerrit Botha; Chester W Brown; Graeme Mardon; Mogomotsi Matshaba; Neil A Hanchard Journal: NPJ Genom Med Date: 2021-03-19 Impact factor: 8.617